NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services’ Molecular ...
NeoGenomics Inc. (NASDAQ:NEO) is one of the most buzzing stocks to buy with the highest upside potential. On February 25, NeoGenomics officially launched RaDaR ST, a tumor-informed circulating tumor ...
NeoGenomics, Inc. recently announced that its PanTracer LBx liquid biopsy test has received Medicare coverage under the MolDX Plasma-Based Genomic Profiling in Solid Tumors policy, allowing eligible ...
-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...
NeoGenomics (NEO) moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a ...
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society ...
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and ...
Southwest Florida companies Hertz, Herc, NeoGenomics, and Alico report Q4 and full-year 2025 earnings, showing mixed results.
NEO recently announced the availability of its new pan-solid tumor assay, PanTracer Pro, designed to help clinicians navigate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results